I. Park

A forecast of typhoid conjugate vaccine introduction and demand in typhoid endemic low- and middle-income countries to support vaccine introduction policy and decisions

V. Mogasale, Enusa Ramani, Jung Seok Lee, 2017, Human vaccines & immunotherapeutics.

Early warning signal for dengue outbreaks and identification of high risk areas for dengue fever in Colombia using climate and non-climate datasets

A. Farlow, V. Herrera, L. Villar, 2017, BMC Infectious Diseases.

Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial

S. Uranw, T. Wartel, Deok-Ryun Kim, 2021, The Lancet. Infectious diseases.

Immune non-interference and safety study of Vi-DT typhoid conjugate vaccine with a measles, mumps and rubella containing vaccine in 9-15 months old Nepalese infants.

Jerome H. Kim, J. Yang, T. Wartel, 2022, Vaccine.